CTA
CCXI

Carillon Tower Advisers’s ChemoCentryx, Inc. CCXI Stock Holding History

Carillon Tower Advisers’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-247,577
Closed -$13.6M – 498
2020
Q3 		$13.6M Buy
+247,577
New +$13.3M 0.18% 211

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Carillon Tower Advisers's CCXI Position: Q4 2020 in Review

Carillon Tower Advisers sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 247,577 shares — an estimated $13.6M sold.

Carillon Tower Advisers first reported a position in CCXI in Q3 2020 and held it in 1 quarter. The position peaked at $13.6M in Q3 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

  • Carillon Tower Advisers reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 247,577 ChemoCentryx, Inc. shares in Q4 2020, an estimated $13.6M.
  • Carillon Tower Advisers first reported a position in ChemoCentryx, Inc. in Q3 2020 and held it in 1 quarter.
  • Carillon Tower Advisers's ChemoCentryx, Inc. position peaked at $13.6M in Q3 2020.
  • 196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.